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 ABSTRACT 
Synthetic oligonucleotides are contaminated with highly homologous 
failure sequences. Oligonucleotide synthesis is difficult to scale up because it 
requires expensive equipments, hazardous chemicals and tedious purification 
process. Here we report a novel thermocyclic reaction, polymerase-endonuclease 
amplification reaction (PEAR), for the amplification of oligonucleotides. A target 
oligonucleotide and a tandem repeated antisense probe are subjected to repeated 
cycles of denaturing, annealing, elongation and cleaving, in which thermostable 
DNA polymerase elongation and strand slipping generate duplex tandem repeats, 
and thermostable endonuclease (PspGI) cleavage releases monomeric duplex  
oligonucleotides. Each round of PEAR achieves >100-fold amplification. The 
product can be used in one more round of PEAR directly, and the process can be 
further repeated. In addition to avoiding dangerous materials and improved 
product purity, this reaction is easy to scale up and amenable to full automation, so 
it has the potential to be a useful tool for large-scale production of antisense 
oligonucleotide drugs. 
Keywords: antisense oligonucleotide; microRNA; thermostable DNA 
polymerase; thermostable endonuclease; DNA amplification  
Introduction  
MicroRNAs (miRNAs) are a family of short noncoding regulatory RNA molecules. 
The miRNA pathway serves as an important post-transcriptional regulation mechanism 
(1). Synthetic antisense oligonucleotides to target miRNAs or their mRNA targets are 
proving to be powerful tools for molecular biology research (2) and may eventually find 
application as new therapeutic agents (3, 4).   
Large quantities (possibly from kilograms to tons) of a specific oligonucleotide have 
to be produced for commercial production of antisense oligonucleotide drugs. Therefore, 
the development of an economical and safe method for industrial production of short 
oligonucleotides has become necessary. Traditional method for de novo oligonucleotide 
synthesizing is the phosphodiester method (5). Using automatic synthesizers, micrograms 
to kilograms of a specific oligonucleotide can be produced in a few hours. Unfortunately, 
however, synthetic oligonucleotides are contaminated with a significant fraction of 
truncated failure sequences, make the product purification process difficult. Moreover, 
the oligonucleotide synthesis process requires not only expensive equipments, but also 
costly and hazardous chemicals. For example, an organic solvent (dichloromethane or 
toluene) must be used to dissolve the deblocking reagent. Therefore, large-scale 
production of oligonucleotides is not only costly, but also involves disposing dangerous 
waste that pose threats to human health and environmental safety.  
In modern molecular biology laboratories, nucleic acids are routinely amplified by 
polymerase chain reaction (PCR). PCR has the limitation, however, of needing a pair of 
synthetic primers. This imposes not only a length constraint on the target DNA, but also a 
yield limit on the PCR product defined by primer concentrations. Therefore, PCR-based 
methods are generally not applicable for the amplification of short oligonucleotides that 
are only about 20 nucleotides (nt) in length. Enzymatic amplification of oligonucleotides 
has been reported by successive rounds of ligation, rolling circle replication (RCR) and 
cleaving (6) or nicking (7), but a laborious recircularization process is required for each 
round of RCR. Here we report a novel thermocyclic reaction, polymerase-endonuclease 
amplification reaction (PEAR), for fast amplification of oligonucleotides. In addition to 
avoid using dangerous materials and improved product purity, this reaction is easy to 
scale up and amenable to full automation, thus enabling large-scale and pollution-free 
antisense oligonucleotide production. 
 
The principle of PEAR 
 A PEAR reaction contains a target oligonucleotide (X), an antisense probe, a 
thermostable DNA polymerase (Taq polymerase), a thermostable endonuclease (PspGI), 
four dNTPs and an appropriate buffer solution. The antisense probe, denoted by X’R’X’, 
is designed to be a single-stranded oligonucleotide contains at least two tandem repeated 
complements of the target sequence (X') that are separated from one another by an 
intervening complementary recognition site (R’) for PspGI.   
As shown in Fig 1, PEAR consists of repetitive cycles of: (1) heat denaturation, (2) 
annealing, (3) elongation and (4) cleaving. In the first cycle, a target oligonucleotide and 
an antisense probe were heat denatured and annealed to form a partial duplex (X/X’R’X’). 
When a target oligonucleotide binds to a probe in the upstream (Fig 1, top right), there is 
no elongation, because it provides no primer/template structure for the Taq polymerase. 
However, as both target and probe are present in a large number of copies, according to 
the law of probability, nearly half of the target oligonucleotides bind to the probe in the 
downstream. In the presence of dNTPs, they are elongated by Taq DNA polymerase to 
form fully matched duplex tandem repeats (XRX/X’R’X’). Subsequently, PspGI cleavage 
of the recognition site releases monomeric oligonucleotides (X/X’). Thereafter, a next 
cycle of denaturation, annealing, elongation and cleaving is started again, resulting in 
exponential amplification of the duplex oligonucleotide. 
In addition, the tandem repeated duplexes are not fully digested by PspGI, because 
the duration of cleaving is rather short. When the remaining tandem repeated duplexes 
are subjected to more cycles of denaturing, reannealing and elongation, the number of 
repeat units increases continually through slipped strand pairing and polymerase 
elongation (Fig 1, right). When PspGI cleavage monomerizes the elongated tandem 
repeats in a following cycle, many more duplex oligonucleotides are released. It is this 
slipping-and-cleaving mechanism that promotes not only the rate of amplification, but 
also the yield of product. Moreover, the PEAR products can be used in a next round of 
PEAR amplification directly without any treatment, and the process can be further 
repeated. The tandem repeated oligonucleotides are thus called seeds, because they can 
reproduce themselves. 
 
Implementation of PEAR 
A synthetic oligonucleotide and an antisense probe derived from human microRNA 
miR-375 were used to validate the proposed reaction mechanism. PEAR reactions with 
complete and incomplete (lacking Taq DNA polymerase, PspGI or target) components 
were conducted under previously optimized reaction conditions with target concentration 
at 1 nM and probe concentration at 100 nM. As shown in Fig 2, a lower band represents 
the duplex product X/X’ and several upper bands represent tandem repeats are observed 
in the complete PEAR reactions, but such bands are not observed if any of the four 
essential components, the two enzymes, the target and the probe, is omitted. We tested 
another three pairs of targets and antisense probes, amplification are all dependent on the 
presence of both of the two enzymes, the target, and the probe (Data not show).  
To determine the sensitivity of PEAR, a series of reactions were conducted with 
target concentrations ranging from 0.1 pM to 1 nM and probe concentration at 100 nM. 
As shown in Fig 3, the yield is very high when target concentration was at 0.1 to 1 nM, 
whereas relatively low when target concentration was < 10 pM.  
 
Hpy99I digestion of the PEAR product 
Although duplex oligonucleotides showed increased cellular uptake when compared 
to single-stranded antisense oligonucleotides (8), and demonstrated improved in vitro 
potency and stability compared to small interfering RNA (9), single-stranded antisense 
oligonucleotides have been more frequently used in practice (10-13). Therefore, it is 
necessary to separate the antisense oligonucleotides from its complementary strands. To 
facilitate the separation of the two complementary strands, we introduced a recognition 
site for restriction enzyme Hpy99I into the probe positioned between the tandem repeats 
and downstream to the recognition site for PspGI. At the end of PEAR, PspGI cleavage 
of the product have resulted in a 5-nt overhang in the 3’-end of the sense strand. After 
PEAR, the product were pooled and further digested with Hpy99I, resulted in another 
5-nt overhang in the 5’-end of the the sense strand (Fig 4). Note that the antisense strand 
is cleaved into 20-nt monomers, and the sense strand is cleaved into monomers that are 
25 or 30 nt in length, allowes convenient separation of them by chromatographic 
methods.  
 
Separation and analysis of the antisense oligonucleotides    
For separation of the antisense oligonucleotides, we used an anion exchange 
chromatography using a SOURCE 15Q column (14). The high pH stability of SOURCE 
15Q allows facile separation of the antisense oligonucleotides from its complementary 
strands under denaturing alkaline conditions at pH 12. The chromatogram shown in Fig 5 
represents the purification of 1 nmol of antisense oligonucleotides. The antisense fraction 
was collected within the window indicated in Fig 5. The 20-nt antisense oligonucleotides 
were separated from the sense strands, short by-products and remaining tandem repeats. 
Collected fraction was further analyzed by anion exchange chromatography and capillary 
electrophoresis. As shown in Fig 6, the purity of the collected fraction analysis by 
chromatography was > 99.0%. Fig 7 shows further analysis of the purified antisense 
oligonucleotide by capillary electrophoresis. The purity was confirmed to be better than 
99.0%. The purity level of this oligonucleotide product is significantly improved when 
compared to that of HPLC-purified synthetic oligonucleotides (14, 20). This is primarily 
due to avoiding of highly homologous impurities, especially (n-1) deletions. 
 
Scale-up and productivity evaluation 
PEAR reactions were run in 96-well plates, with 95x100 µL PEAR reactions and a 
no target control (NTC) in each run. To demonstrate the ability to scale up, three 
successive rounds of PEAR were conducted, respectively at scales of 1, 100 and 500 runs. 
The product of round 1 was used diluted 1:100 as seeds for round 2 directly without any 
treatment, and that of round 2 for round 3. After cleavage and purification, the quantity of 
purified antisense oligonucleotide was given by measuring its optical density at a 
wavelength of 260 nm. The average concentrations, purities, yields and total yields of 
recoverable (purified) products are estimated and summarized in Table 1. On average, the 
concentration of purified product is about 10 µM or 70 ng/µl, which is ~100-fold higher 
than the input concentrations. The average yield of purified product of a single run is 
about 0.67 mg, which is greater than the typical yield of HPLC-purified product of a 
1-µmole scale commercial synthesis. The total yield of round 2 (a 100-fold scale-up of 
round 1) was increased to ~67 mg; and that of round 3 (a 5-fold scale-up of round 2), was 
further increased to ~336 mg, demonstrated that this method is well suited to scale up.  
 
Discussion 
MiRNAs plays an important role in post-transcriptional gene silencing that is highly 
conserved among species (1). Synthetic antisense oligonucleotides to target miRNAs or 
their target mRNAs have been proving to be powerful tools to specifically and selectively 
regulate the expression of genes, and to investigate the roles of dysregulated genes in 
human diseases (2). MiR-375, for example, is highly expressed in pancreatic islets and is 
required for glucose homeostasis that is conserved in zebrafish, mice and human (15, 16). 
Obese mice exhibit increased miR-375 expression, and genetic deletion of miR-375 
resulted in a severe diabetes (17). Targeted inhibition of miRNA with a modified 
antisense oligonucleotide reveals the role for miR-375 in pancreatic islet (18).  
Antisense oligonucleotides to target miRNAs or mRNA are expected to be capable 
of curing a wide variety of human diseases, including cancer, obesity, cardiovascular and 
metabolic diseases (3, 4). By far, antisense oligonucleotides are all manufactured by 
solid-support phosphoramidite-coupling chemistry (8-14). Dichloromethane (CH2Cl2), a 
halogenated solvent, was used to dissolve the deblocking reagent (trichloroacetic acid, 
TCA, or dichloroacetic acid, DCA). As oligonucleotide synthesizers are now available 
for syntheses in large scale, the quantity of chlorinated waste generated becomes quite 
large (19). The high toxicity, high volatility and carcinogenicity of dichloromethane are 
leading to stringent regulation by regulatory agencies. Replacement of dichloromethane 
with toluene, a recyclable non-halogenated solvent, eliminated the production of large 
quantities of chlorinated waste (19). Toluene, however, is a highly volatile, flammable 
liquid with strong odor, and is still harmful to human health and environmental safety. 
Typically, crude products from solid-support organic synthesis is contaminated with 
a significant fraction of highly homologous failure sequences that arise from incomplete 
detritylation, coupling, sulfurization, capping or deprotection (20). The most significant 
impurities found in synthetic oligonucleotides are the (n-1) deletions that differ from the 
full-length product by lacking only one of the necessary nucleotides. For oligonucleotides 
18–21 nucleotides in length, it is difficult to remove the (n-1) deletions completely from 
full-length oligonucleotides by HPLC (20).  
As a novel, simple method for the amplification of short oligonucleotides, PEAR is 
capable of solving all above problems. The basic raw materials, nucleotides and enzymes, 
are all safe, inexpensive and pollution-free. Hence, although a small-scale synthesis of 
the seeds is still a prerequisite, the use of hazardous chemicals is reduced to a minimum. 
Moreover, due to avoiding of (n-1) deletions, purification of the antisense oligonucleotide 
is made easy, and the purity level of the product is also improved.  
For the majority of existing DNA amplification technologies, including polymerase 
chain reaction (PCR) (23), ligase chain reaction (LCR) (24), rolling circle amplification 
(RCA) (25), loop-mediated isothermal amplification (LAMP) (26), strand displacement 
amplification (SDA) (27) and helicase-dependent amplification (HDA) (28), all needs a 
pair of short synthetic primers to achieve exponential amplification. The yields of the 
final products are inherently dependent on and limited by input primer concentrations. 
Exponential amplification reaction (EXPAR) is a fast isothermal reaction that can 
achieve 106-fold amplification of a target oligonucleotide in 10 min (29). However the 
utility of EXPAR is currently limited, as serious nonspecific background amplification 
was reported (30). Moreover, obviously in EXPAR DNA synthesis proceeds in only one 
of the two strands (the target strand), but not in the other (the antisense strand), so the 
product yield is still limited by the input concentration of the antisense template. 
Noteworthy, rolling-circle replication (RCR) proceeds in a linear fashion using the 
highly processive phi29 DNA polymerase can copy a circular probe into a DNA strand 
containing >1,000 tandem repeated complements of a circularized DNA molecule (25). 
Circle-to-circle amplification (C2CA), a multistep RCR-based process for strand-specific 
amplification of circularized DNA (6), has been used for the amplification of DNA 
circles, in which tandem repeated complements of DNA circles are generated by RCR, 
and converted to monomeric circles of opposite polarity to that of the starting material. 
Billion-fold amplifications was achieved through successive rounds of ligation, RCR and 
cleaving, however a laborious cleavage, ligation and recircularization process is required 
for each round of RCR amplification. Moreover, a synthetic ligation template is required 
to recircularize and monomerize the tandem repeated complements, so this technique 
requires the additional production of large amounts of ligation templates. This problem 
was eliminated by using a hairpin-containing self-templating oligonucleotide that 
contains a suicide cassette, a recognition site for a nicking enzyme, and recircularizing 
and monomerizing the tandem repeated complements by nicking the suicide cassette (7), 
however, a laborious nicking, ligation and recircularization process is still needed for 
each generation of RCR, makes it not readily amenable to automation. 
In contrast, PEAR is a simple but effective method for the amplification of short 
oligonucleotides through the unique slipping-and-cleaving mechanism. As is evident 
from the data presented here, one round of PEAR amplification can result in >100-fold 
increment in product yield. We have observed >1000-fold in PEAR reactions (data not 
show), but we adopted a one hundred-fold amplification for the scale-up reactions in this 
study, because it provides more reliable and uniform product yield. Three rounds of 
PEAR starting from micrograms of seeds produced more than three hundred milligrams 
of products. Thus more rounds of PEAR starting from these hundred-milligram seeds can 
yield dozen-grams, then kilograms, and then tons, of products. Thus, one hundred-fold 
scale-up is sufficient for large-scale oligonucleotide production. 
In this preliminary study, we demonstrated only the production of an unmodified 
antisense oligonucleotide. Modified antisense oligonucleotides, such as phosphorothioate 
oligodeoxynucleotides (21), 2'-O-methoxyethyl (10-12), 2'-O-methyl (11-12) or 2'-fluoro 
substituted oligonucleotides (11-12), and locked nucleic acid (11-13), are reported to 
demonstrate increased stability and potency when compared to its native counterparts. 
Inspiringly, modified DNA bearing 5(methoxycarbonylmethyl)-2'-deoxyuridin has been 
prepared in large scale by PCR and postsynthetic derivatization (22), implies that it might 
be feasible to prepare modified oligonucleotides in large scale by PEAR amplification 
and/or postsynthetic derivatization. 
Finally, PEAR amplification of antisense oligonucleotides uses much less expensive 
thermocyclers instead of highly expensive DNA synthesizers. The cost of equipments in 
large-scale production of oligonucleotide could be reduced greatly. The cost of raw 
materials could also be cut down sharply if they were used in bulk quantities. Because the 
product can be used as seeds in a next round of amplification directly without any 
treatment, so the process is readily amenable to full automation. In conclusion, the ability 
of PEAR to avoid handling of dangerous chemicals, simplified product purification, 
improved product purity, easy to scale up and amenable to automation would all be 
beneficial when compared to traditional organic synthesis. So it might be worthwhile to 
replace organic synthesis with this simple, safe and economic method in large-scale 
production of oligonucleotide drugs. 
  
Materials and methods  
Enzymes and oligonucleotides 
Taq DNA Polymerase and restriction enzymes, PspGI and Hpy99I, were purchased 
from New England Biolabs. A target oligonucleotide and two antisense probes to target 
human microRNA miR-375 were custom synthesized and HPLC-purified by Invitrogen 
Life technologies. The sequence of the target oligonucleotide is 5'-TGT TCG TTC GGC 
TCG CGT GA-3'. Both of the two probes contain three tandem repeated complements of 
the target sequence (X'). The first probe (X'R'X'R'X') was used for validation of the 
reaction mechanism, in which the three complements are separated from each other by a 
recognition site (R') for PspGI. The second probe (X'R'H'X'R'H'X') was used in scale-up 
reactions, in which two recognition sites (R' and H'), respectively for PspGI and Hpy99I, 
are embedded between the repeats. The sequence of the first probe is 5'-TCA CGC GAG 
CCG AAC GAA CAC CAG GTC ACG CGA GCC GAA CGA ACA CCA GGT CAC 
GCG AGC CGA ACG AAC A-3', and that of the second probe is 5'-TCA CGC GAG 
CCG AAC GAA CAC CAG GTT TTC GAC GTC ACG CGA GCC GAA CGA ACA 
CCA GGT TTT CGA CGT CAC GCG AGC CGA ACG AAC A-3'. The purity of the 
target oligonucleotide and probes received was ~95.0%. They were repurified at home by 
anion exchange chromatography to achieve >99.0% purity.  
PEAR reactions 
PEAR were carried out in 96-well plates on a Applied Biosystems 9700 Thermal 
Cycler, each in a 100 µL volume reaction mixture containing 200 µM each dNTP, 15 
mM Tris-HCl, 30 mM KCl, 5 mM (NH4)2SO4, 2.5 mM MgCl2, 0.02 % BSA, 0.08 u/µl 
Taq DNA polymerase, 0.4 u/µl PspGI restriction enzyme, desired amount of target 
oligonucleotide and antisense probe. The reactions were initiated at 95°C for 1 min, 
followed by 30 cycles of denaturing at 94°C for 15 sec, annealing at 55 °C for 35 sec, 
elongation and cleaving at 75°C for 5 min. If desired, PspGI digestion of the product is 
conducted by a final incubation at 75°C for 30 min. PEAR products were separated by 
15% non-denaturing polyacrylamide gel electrophoresis (PAGE), and visualized under an 
ultraviolet illuminator after SYBR Gold staining (Molecular Probes).  
Cleavage, separation, purification and quantification 
The PEAR products were pooled and fully digested by the addition of 1 volume of 
cleavage mixture containing 1× NEBuffer 4, and 1.0 u/μl of Hpy99I. Cleavage reactions 
were incubated for 3 hours at 37°C and stopped by heat inactivation at 65°C for 20 
minutes. Separation and purification of the antisense oligonucleotide were performed by 
anion exchange chromatography using ÄKTA explorer™ 10 system (GE Healthcare) as 
described (14). SOURCE Q PE 4.6/100 prepacked analytical columns filled with 
polymer-based, 15 μm monosized beads were purchased from GE Healthcare. The 
column effluent was fractionated and collected using a Frac-950 Fraction Collector (GE 
Healthcare). The volume of collected fraction was 0.5 column volume (CV). The 
chromatographic conditions are described in the legend to Fig 5. A HiPrep™ 26/10 
column (GE Healthcare) was employed for desalting the purified oligonucleotide using 
MilliQ™ ultrapure water (Millipore Corporation, Billerica, USA) as eluent. The mass 
estimates of the purified antisense oligonucleotide were given by 260 nm absorbance 
measurements of diluted samples. Data were analyzed in Microsoft Excel. 
Purity analysis  
The purity of purified antisense oligonucleotide was analyzed by anion exchange 
chromatography as described (14). The anion exchange HPLC analysis was conducted on 
Hewlett-Packard Model 1100 liquid chromatography (Palo Alto, CA, USA) fitted with a 
non-porous medium DNAPac PA-100 4/250 mm analytical column (Dionex Corporation, 
Sunnyvale, CA, USA), thermostatted to 25C and operated at a flow rate of 480 cm/h. The 
chromatographic conditions are described in the legend to Fig 6.   
Capillary electrophoresis was performed using a 50-µm I.D.×20-cm (effective 
length 18 cm) capillary. The capillary was treated with PlusOne™ Bind-Silane (GE 
Healthcare) and filled with polyacrylamide cyclodextrin gel. Buffer was consisted of 0.1 
M Tris-0.25 M boric acid, pH 8.5, containing 7 M urea. Injection was made at 1 kV for 5 
sec. Analysis was performed at 1.5 kV for 30 min.  
  
 
Fig 1. Schematic description of PEAR. Sense and antisense strands are represented respectively by 
solid and dashed lines, the 3’ ends are indicated by arrows and the restriction sites for PspGI are 
indicated by solid diamonds. When a target oligonucleotide (X) binds to a probe in the upstream, it is 
elongated by a Taq DNA polymerase, a full-duplex contains tandem repeats is produced. If the repeats 
are cleaved by PspGI, short duplex oligonucleotides (X/X’) are released; and if they are not cleaved, 
the number of tandem repeats increases by slipping and elongation.  
  
 
Fig 2. PEAR reactions with complete and incomplete components. Target (X) and probe (X'R'X'R'X') 
concentrations were respectively at 1nM and 100 nM. For PspGI, H and L stand respectively for high 
(0.4 unit/µL) and low (0.1 unit/µL) concentrations. Lane M: Invitrogen Trackit™ 10bp DNA ladder; 
Lane 1-2: complete PEAR reactions containing Taq DNA polymerase, PspGI, the target and the probe. 
The lower band (show by an arrow) represents the 20-bp duplex monomers, and the upper bands 
represent tandem repeats; Lane 3-9: incomplete PEAR reactions lacking one or both of the two 
enzymes or the target. No product band is observed. The bands represent probe self dimers formed by 
intermolecular interactions. 
 
 
  
Fig 3. PEAR reactions with different target concentrations. Lane M: Invitrogen Trackit™ 10bp DNA 
ladder; lane 2-8: PEAR reaction with 1 to 10-4 nM of input oligonucleotides. Probe (X'R'X'R'X') 
concentration is at 100 nM. A final incubation at 75C for 30 min was conducted to cleave the product.  
 
 
 
           
 
B (25nt)         PspGI     E     Hpy99I           C (30nt)           PspGI    E    Hpy99I  
(+):  3’-AGTGCGCTCGGCTTGCTTGT GGTCC^ AAAA ^GCTGC AGTGCGCTCGGCTTGCTTGT GGTCC^AAAA^GCTGC ......-5’ 
- - - - - | | | | | | | | | | | | | | | | | | | | - | | | | | - | | | | - | | | | | - | | | | | | | | | | | | | | | | | | | | - | | | | | - | | | | - | | | | | - - - - 
(-):  5’-TCACGCGAGCCGAACGAACA^CCAGG TTTT CGACG^TCACGCGAGCCGAACGAACA^CCAGG TTTT CGACG^......-3’ 
         1         A (20nt)          20    D (14nt)         34       A (20nt)             54        D (14nt)    68 
Fig 4. Double digestion of the PEAR product by PspGI and Hpy99I. The sense and the antisense 
strand are indicated respectively by (+) and (-). Recognition sites for PspGI and Hpy99I are 
underlined and marked. Each position where cleavage was expected to occur is indicated by a caret 
(“^”). The antisense strands (A) are black boxed, the sense strands (B and C) are boxed, and the 
by-products (D and E) are grey boxed. The expected length for each strand is indicated in parenthesis. 
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Fig 5. HPLC separation and purification of antisense oligonucleotide. Fractions are indicated by letter 
A to E as shown in Fig 4. Fraction A, which contains the antisense strands, was collected in the 
indicated interval. Sample: 10 µg PEAR product double digested by PspGI and Hpy99I; Column: 
SOURCE Q PE 4.6/100; Flow rate: 1 ml/min; Buffer A: 10 mM NaOH, pH 12; Buffer B: 10 mM 
NaOH + 2M NaCl, pH 12; Gradient: 20–35% B in 50 column volume.  
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Fig 6. HPLC analysis of purified antisense oligonucleotide. Sample: 25 µL purified antisense 
oligonucleotide; Column: DNAPac PA-100 (4/250); Flow rate: 1 ml/min; Buffer A: 10 mM NaClO4 + 
1 mM Tris; Buffer B: 300 mM NaClO4 + 1 mM Tris; Gradient: 10–70% B, 7.6 CV.  
  
Fig 7. Capillary electrophoresis of HPLC purified antisense oligonucleotide. Capillary: 50 µm×18 cm, 
filled with polyacrylamide cyclodextrin gel; Buffer: Tris-borate/Urea; Running conditions: 1.5 kV/30 
min; Sample application: 1 kV/5 s. 
 
  
Table 1. Average recoverable concentration, purity and yield of purified antisense oligonucleotide 
Round# a  Runsb 
Average recoverable 
concentration Purity d 
Recoverable Yield 
(mg) 
 (µM)  (ng/µl ) Average Total 
1 1c 10.543  70.966  99.18% 0.674  0.674  
2 100 10.579  71.209  99.17% 0.676  67.649  
3 500 10.524  70.840  99.17% 0.673  336.490  
a. The product of round 1 was used as seeds for round 2, and that of round 2 for round 3. 
b. Each run consisted 95x100 µl reactions. Target and probe concentration are respectively at 1 
nM and 100 nM.  
c. Round 1 had two duplicate runs. As the first run had been used as seeds, the second run was 
used for purification and analysis. 
d. Purity was calculated as peak area% at UV 260 nm.  
 
References 
[1] Ambros V. 2004. The functions of animal microRNAs. Nature 431:350–355. 
[2] Esau CC. 2008. Inhibition of microRNA with antisense oligonucleotides. Methods. 44(1):55-60. 
[3] Weiler J, Hunziker J, Hall J. 2006. Anti-miRNA oligonucleotides (AMOs): ammunition to target 
miRNAs implicated in human disease? Gene Ther. 13(6):496-502. 
[4] Rayburn ER., Zhang R. 2008. Antisense, RNAi, and Gene Silencing Strategies for Therapy: Mission 
Possible or Impossible? Drug Discov Today. 13(11-12): 513–521 
[5] Brown EL, Belagaje R, Ryan MJ, Khorana HG. 1979. Chemical synthesis and cloning of a 
tyrosine tRNA gene. Methods Enzymol. 68:109–151. 
[6] Dahl F, Ban é r J, Gullberg M, Mendel-Hartvig M, Landegren U, Nilsson M. 2004. 
Circle-to-circle amplification for precise and sensitive DNA analysis. Proc Natl Acad Sci U S A. 
101 (13):4548-53. 
[7] Lohmann JS, Stougaard M, Koch J. 2007. A new enzymatic route for production of long 
5'-phosphorylated oligonucleotides using suicide cassettes and rolling circle DNA synthesis. 
BMC Biotechnol. 7:49. 
[8] Astriab-Fisher A, Fisher MH, Juliano R, Herdewijn P. 2004. Increased uptake of antisense 
oligonucleotides by delivery as double stranded complexes, Biochem. Pharmacol. 68, 403–407 
[9] Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A, Wanders L, Griffey RH, 
Swayze EE, Bhat B. 2005. Fully 2'-Modified Oligonucleotide Duplexes with Improved in Vitro 
Potency and Stability Compared to Unmodified Small Interfering RNA, J. Med. Chem. 48, 
901-904 
[10] Butler M, Hayes CS, Chappell A, Murray SF, Yaksh TL, Hua XY. 2005. Spinal distribution and 
metabolism of 2’-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration 
in rats, Neuroscience, 131 (3): 705-715 
[11] Davis S, Propp S, Freier SM, Jones LE, Serra MJ, Kinberger G, Bhat B, Swayze EE, Bennett CF, 
Esau C. 2009. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res. 
37(1):70-7 
[12] Davis S, Lollo B, Freier S, Esau CC. 2006. Improved targeting of miRNA with antisense 
oligonucleotides, Nucleic Acids Res., 34 (8): 2294–2304 
[13] Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z, Yang B. 2009. A single anti-microRNA antisense 
oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach 
for microRNA interference. Nucleic Acids Res. 37(3): e24. 
[14] Shanagar J. 2005. Purification of a synthetic oligonucleotide by anion exchange 
chromatography: method optimisation and scale-up. Biochem Biophys Methods. 64(3):216-25. 
[15] Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. 2004. A pancreatic islet-specific 
microRNA regulates insulin secretion. Nature 432: 226–230. 
[16] Avnit-Sagi T, Kantorovich L, Kredo-Russo S, Hornstein E, Walker MD. 2009. The promoter of 
the pri-miR-375 gene directs expression selectively to the endocrine pancreas. PLoS One. 
4(4):e5033 
[17] Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, Zavolan M, Stoffel M. 2009. 
MiR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A. 
106(14):5813-8. 
[18] Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. 2007. Targeted 
inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet 
development. PLoS Biol 5:e203. 
[19] Krotz AH., Carty RL., Scozzari AN., Cole DL., Ravikumar VT. 2000. Large-Scale Synthesis of 
Antisense Oligonucleotides without Chlorinated Solvents, Organic Process Research & 
Development, 4: 190-193 
[20] Gilar M. 2001. Analysis and Purification of Synthetic Oligonucleotides by Reversed-Phase 
High-Performance Liquid Chromatography with Photodiode Array and Mass Spectrometry 
Detection, Analytical Biochemistry, 298, 196–206 
[21] Balotta C, Lusso P, Crowley R, Gallo RC, Franchini G. 1993. Antisense phosphorothioate 
oligodeoxynucleotides targeted to the vpr gene inhibit human immunodeficiency virus type 1 
replication in primary human macrophages. J. Virol. 67(7):4409-4414 
[22] Mehedi Masud M, Ozaki-Nakamura A, Kuwahara M, Ozaki H, Sawai H. 2003. Modified DNA 
bearing 5(methoxycarbonylmethyl)-2'-deoxyuridine: preparation by PCR with thermophilic 
DNA polymerase and postsynthetic derivatization. Chembiochem. 4(7):584-8. 
[23] Saiki, RK; Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. 1985. Enzymatic 
amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of 
sickle cell anemia. Science 230 (4732): 1350–1354 
[24] Barany F. 1991. Genetic disease detection and DNA amplification using cloned thermostable 
ligase. Proc. Natl. Acad. Sci. USA. 88(1):189-93 
[25] Lizardi PM, Huang X, Zhu Z, Bray-Ward P, Thomas DC, Ward DC. 1998. Mutation detection 
and single-molecule counting using isothermal rolling-circle amplification. Nat. Genet. 19 (3): 
225–232. 
[26] Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. 2000. 
Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 28: E63 
[27] Walker GT, Little MC, Nadeau JG, Shank DD. 1992. Isothermal in vitro amplification of DNA 
by a restriction enzyme/DNA polymerase system. Proc Natl Acad Sci U S A. 89(1):392–396. 
[28] Vincent M, Xu Y, Kong H. 2004. Helicase-dependent isothermal DNA amplification, EMBO 
reports 5(8): 795–800 
[29] Van Ness J, Van Ness LK, Galas DJ. 2003. Isothermal reactions for the amplification of 
oligonucleotides, Proc Natl Acad Sci U S A., 100 (8): 4504–4509 
[30] Tan E, Erwin B, Dames S, Ferguson T, Buechel M, Irvine B, Voelkerding K, Niemz A. 2008. 
Specific versus nonspecific isothermal DNA amplification through thermophilic polymerase and 
nicking enzyme activities. Biochemistry. 47(38):9987-9999 
 
Acknowledgements 
This research was supported by the National Science Foundation of China. 
